Ocular, systemic and antinuclear antibody changes with acebutolol.
A group of 29 hypertensive patients were studied for side effects of acebutolol. An antinuclear antibody titre of >/=1/64 developed in 23 per cent of patients during a 12-month course of treatment. Full ophthalmic examination before and after the treatment period showed a statistically significant increase in tear secretion at one year. One patient had a slight worsening of her psoriasis. No patients developed any symptoms or signs of oculomucocutaneous syndrome (OMCS) or systemic lupus erythematosus (SLE).
D000070:Acebutolol / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis*; D005128:Eye Diseases / Q000139:chemically induced*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013666:Tears / Q000187:drug effects
D000974:Antibodies, Antinuclear; D000070:Acebutolol